A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS

计划入组 50 人 · 首次发布于 2019 年 3 月 21 日

Study of Orally Administered TAK-960 in Patients With Advanced Nonhematologic Malignancies

计划入组 32 人 · 首次发布于 2010 年 8 月 11 日

Study to Assess the Pharmacokinetics and Pharmacodynamics of GSK461364 in Subjects With Non-Hodgkins Lymphoma

计划入组 41 人 · 首次发布于 2007 年 9 月 28 日

Polo-like kinase-1/bora gene interaction inhibitor ( InnoPharmaScreen)

cdc2-like kinases/Dyrk1A inhibitors (NCATS)

TNCE-7

Notable Labs

Israel

Cardiff Oncology

United States

NHI-1

United States

Sillajen Presents Clinical Study Overview of Anticancer Drug BAL0891 at International Symposium

Cardiff Oncology's Onvansertib Enters Phase 2 Trial for KRAS/NRAS-Mutated Metastatic Colorectal Cancer

Rigosertib Achieves 80% Response Rate in First Clinical Trial for Rare RDEB-Associated Skin Cancer